Hyundai Motor collaboration, Hanmi technology transfer and NeuroFit certification among latest news
Brokerages and companies announced news about Hanmi Pharmaceutical’s technology transfer, Hyundai Motor’s collaboration with Boston Dynamics, Hyundai Mobis’ actuator outlook, and Hyundai Motor and Kia’s 5monthly sales, as well as NeuroFit’s information security certification. Some stocks saw their target prices raised, while sales trends were mixed.
Recent announcements by brokerages and companies covered Hanmi Pharmaceutical’s technology transfer, Hyundai Motor’s collaboration with Boston Dynamics, Hyundai Mobis’ actuator outlook, 5monthly sales results, and NeuroFit’s information security certification. The news was conveyed through brokerage reports and company announcements. Target price increases were reported for some stocks.
Kiwoom said Hanmi Pharmaceutical’s technology transfer demonstrated the strength of its R&D capabilities. Hanmi Pharmaceutical announced a technology transfer agreement for the substance. Kiwoom raised its target price on that basis.
Daol said Hyundai Motor’s collaboration with Boston Dynamics had entered a more concrete stage. On this basis, Daol set Hyundai Motor’s target price at 100ten thousand won. The report said there had been progress related to the collaboration.
KB gave a positive assessment of the outlook for Hyundai Mobis’s actuator business. It raised its target price, citing the business’s growth potential. The report pointed to product demand and business expansion.
Hyundai Motor and Kia’s 5monthly sales showed mixed results. Hyundai Motor’s sales slowed due to parts shortages. Kia reported an expansion in sales centered on eco-friendly vehicles.
NeuroFit obtained an international information security certification. The company said the certification had enhanced its credibility. The certification reflects an external assessment of the security level of its products and services.